Home – Enhanced Due Diligence: Your Prescription for Mitigating Risk in Pharma Supply Chain

Enhanced Due Diligence: Your Prescription for Mitigating Risk in Pharma Supply Chain

Posted on 07-29-2015 by Ulyana Androsova

Faced with increasing globalization and supply chain complexity, pharmaceutical companies have the daunting task of managing risks—ranging from counterfeiting to piracy—that could potentially threaten patient safety. What’s more, the pharmaceutical industry is not immune to the impact of stricter laws and sanctions to counter bribery and corruption.

On a recent webinar, LexisNexis Segment Leader for Entity Due Diligence and Monitoring Mark Dunn discussed how anti-money laundering, anti-bribery and corruption enforcement trends effecting the pharmaceutical industry.  He also reviewed regulator expectations for staying compliant within a global business environment and shared best practices around risk assessment and why a healthy due- diligence strategy is the best approach to reducing regularity risk.

Ways to Apply This Information Now

  • View the Webinar recording to learn if your due-diligence process needs a check-up.
  • Download How Due Diligence and On-Going Monitoring Alleviates Healthcare Supply Chain Risk to understand the pains in the Pharma supply chain and what you can do to mitigate risk.
  • Explore LexisNexis® solutions that support due diligence and on-going monitoring to reduce risk.

Your comment has been posted.   Close
Thank you, your comment requires moderation so it may take a while to appear.   Close